Report on Strategies for Responding to Drug Pricing System Reform Released

Following the reform of the drug pricing system, domestic pharmaceutical companies will need to restructure their product portfolios and focus on their core businesses, according to a report.


Samil PwC said on November 18 that it had published a report titled "Drug Pricing System Reform: Strategic Choices for Traditional Pharmaceutical Companies." The reform centers on adjusting the pricing system for generics and medicines whose patents have expired. The report said the competitiveness of generic drug businesses could vary depending on the profitability and product differentiation of individual products, as well as each company's research and development (R&D) and manufacturing and supply capabilities.


The report analyzed that because costs such as production facilities cannot be reduced in the short term even if drug prices fall, profits could decline more sharply than revenue, potentially limiting companies' capacity to invest in R&D in the future. It also noted that the impact could be greater on companies with a high share of revenue from domestic reimbursed generics and a heavy fixed-cost burden.

Samil PwC: "Pharmaceutical Companies Should Restructure Products Amid Drug Pricing Reform" View original image

The report proposed four strategies for domestic pharmaceutical companies: defending existing cash flows, differentiating products, diversifying businesses, and consolidating and restructuring businesses and assets.


To defend existing cash flows, it recommended improving costs for individual products and concentrating resources on key products with strong economic viability. For product differentiation, companies should secure products that are challenging to develop and manufacture, it said. It also said they should reduce their reliance on domestic reimbursed generics by expanding exports. The report recommended securing scale or expertise through product transfers, joint production and sales, and selective mergers and acquisitions (M&A).



Seo Yongbeom, pharmaceutical and biotech industry leader (partner) at Samil PwC, said, "This drug pricing system reform will give pharmaceutical companies focused on generics an opportunity to reassess the economic viability of individual products and how they allocate capital. It is important to manage the cash-generating capacity of existing businesses while investing in differentiated products and manufacturing and supply capabilities that match each company's strengths, and to secure capabilities they need through product acquisitions, M&A, or partnerships."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing